News | June 02, 2008

GE Focuses on PET-VCAR Innovations at ASCO

June 3, 2008 – GE showcased at ASCO its latest advances in molecular imaging technologies such as the IN Cell Analyzer, Positron Emission Tomography/Volume Computer Assisted Reading (PET-VCAR) and Fastlab automated PET radiopharmacy, aiming to help healthcare providers understand the molecular root of diseases and explore new paths for detecting, treating and monitoring illnesses earlier.

PET-VCAR is a complement to GE’s approach to personal patient management. The system reportedly helps optimize tumor management by enabling early quantification and evaluation of treatment effectiveness, a valuable tool for treatment planning. It features workflow enhancements for both single and multi-exam review, and includes exam-to-exam auto-registration; tumor segmentation and quantification; and multiplanar image review.

IN Cell Analyzer System from GE’s Life Science Division, represents a complete solution for high-content sub-cellular analysis. Used in research and drug discovery, the system performs assays directly inside cells and uses image analysis techniques to give quantitative results for those assays for each individual cell. The power of the IN Cell Analyzer comes from using the high throughput it delivers to analyze thousands of cells under different conditions to generate statistically robust data.

Fastlab is the first multitracer PET chemistry synthesis platform to feature a cassette that incorporates premeasured, preloaded reagents—an innovation that reportedly delivers higher yields, improved reproducibility and faster synthesis than any other platform. It is designed to accommodate different chemistries, facilitating the production of multiple PET tracers. The first application launched on the platform is FDG. GE Healthcare is planning to expand the utility of the platform by developing a range of other radiopharmaceuticals, including GE Healthcare proprietary diagnostic imaging agents.

The GE Signa Vibrant is a dedicated 1.5T breast MR scanner utilizing High Definition technology and applications specifically designed for breast MR, including: VIBRANT acquisition, BREASE spectroscopy, integrated CADstream (manufactured by Confirma) and a specially designed breast MR patient table designed to provide optimal imaging and outstanding access for intervention. Signa Vibrant’s design is said to be ideally suited for the environment of many breast-imaging centers.

GE helps physicians take aim at cancer with their Advanced Imaging technologies for radiation therapy planning. GE’s radiation therapy solutions include advanced imaging technologies with LightSpeedRT16 wide-bore multislice CT simulator, Discovery PET-CT scanner, Signa MR system and radiation oncology simulation software, providing tools geared at maximizing the potential of new treatment delivery technologies.

GE also showcased solutions from its Centricity portfolio, including the Centricity Electronic Medical Record, Practice Solution and PACS. With users reportedly ranging from the nation’s largest healthcare organization to the solo practitioner, the Centricity EMR is an ambulatory system relied on by more than 30,000 clinicians nationwide. Centricity Practice Solution is a completely integrated clinical and financial management solution aimed to provide a singular approach to a more efficient, high quality practice – extending from the patient’s first visit to final reimbursement.

For more information: www.gehealthcare.com

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
PET Tracer Measures Damage From Multiple Sclerosis in Mouse Models
News | PET Imaging | January 24, 2018
January 24, 2018 — The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallma
Overlay Init